

# Tomas Hanke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5304140/publications.pdf>

Version: 2024-02-01

119  
papers

5,676  
citations

87888

38  
h-index

85541

71  
g-index

122  
all docs

122  
docs citations

122  
times ranked

4591  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adenovirus DNA Polymerase Loses Fidelity on a Stretch of Eleven Homocytidines during Pre-GMP Vaccine Preparation. <i>Vaccines</i> , 2022, 10, 960.	4.4	1
2	Growth patterns and their contributing factors among HIV-exposed uninfected infants. <i>Maternal and Child Nutrition</i> , 2021, 17, e13110.	3.0	11
3	Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 741-753.	4.1	9
4	Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination. <i>Npj Vaccines</i> , 2021, 6, 117.	6.0	3
5	Tetavalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. <i>Vaccines</i> , 2020, 8, 360.	4.4	12
6	Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice. <i>Vaccines</i> , 2020, 8, 678.	4.4	4
7	Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. <i>Vaccine</i> , 2020, 38, 5036-5048.	3.8	13
8	MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	20
9	In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCNO2 HIV-1 Kick&Kill Clinical Trial. <i>Frontiers in Immunology</i> , 2020, 11, 418.	4.8	23
10	Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya. <i>Vaccines</i> , 2020, 8, 260.	4.4	5
11	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. <i>Lancet, The</i> , 2020, 395, 888-898.	13.7	98
12	Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines. <i>Vaccines</i> , 2020, 8, 28.	4.4	8
13	HIVconsV Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCNO2). <i>Frontiers in Immunology</i> , 2020, 11, 823.	4.8	55
14	Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. <i>Vaccines</i> , 2019, 7, 78.	4.4	16
15	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EclinicalMedicine</i> , 2019, 11, 65-80.	7.1	52
16	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsVX Conserved Mosaic-Specific T Cells against HIV-1. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 148-160.	4.1	4
17	Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsV vaccines in preventive and therapeutic clinical trials. <i>Expert Review of Vaccines</i> , 2019, 18, 1029-1041.	4.4	26
18	Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens. <i>Journal of Virology</i> , 2019, 93, .	3.4	26

#	ARTICLE	IF	CITATIONS
19	Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. <i>Frontiers in Immunology</i> , 2019, 10, 923.	4.8	16
20	Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epitope vaccine. <i>PLoS Pathogens</i> , 2019, 15, e1007564.	4.7	20
21	MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 253-264.	4.1	14
22	PO 8515â€¦CAPACITY BUILDING IN PREPARATION FOR AN HIV VACCINE TRIAL: THE GLOBALLY RELEVANT AIDS VACCINE EUROPE-AFRICA TRIALS PARTNERSHIP (GREAT). <i>BMJ Global Health</i> , 2019, 4, A48.1-A48.	4.7	0
23	OC 8499â€¦THE T-CELL VACCINE STRATEGY: GLOBALLY RELEVANT AIDS VACCINE EUROPE-AFRICA TRIALS PARTNERSHIP (GREAT). <i>BMJ Global Health</i> , 2019, 4, A10.3-A11.	4.7	0
24	Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 32-46.	4.1	74
25	Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. <i>PLoS ONE</i> , 2018, 13, e0197299.	2.5	13
26	Identification of novel HIV-1-derived HLA-E-binding peptides. <i>Immunology Letters</i> , 2018, 202, 65-72.	2.5	21
27	CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. <i>Retrovirology</i> , 2018, 15, 46.	2.0	37
28	A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. <i>Frontiers in Immunology</i> , 2018, 9, 3175.	4.8	27
29	HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. <i>Molecular Therapy</i> , 2017, 25, 494-503.	8.2	19
30	Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1798-1810.	3.3	15
31	Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. <i>Nature Immunology</i> , 2017, 18, 762-770.	14.5	147
32	Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. <i>Journal of the International AIDS Society</i> , 2017, 20, 21171.	3.0	36
33	Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. <i>PLoS ONE</i> , 2017, 12, e0176418.	2.5	27
34	Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens. <i>PLoS ONE</i> , 2017, 12, e0181382.	2.5	19
35	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. <i>PLoS ONE</i> , 2017, 12, e0181886.	2.5	16
36	A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data. <i>Journal of Immunological Methods</i> , 2016, 435, 43-49.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5682-5687.	7.1	51
38	Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. <i>European Journal of Immunology</i> , 2016, 46, 60-69.	2.9	57
39	The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 944-946.	1.1	1
40	Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16061.	4.1	39
41	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. <i>Molecular Therapy</i> , 2016, 24, 832-842.	8.2	107
42	Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. <i>Molecular Therapy</i> , 2016, 24, 375-384.	8.2	35
43	Control of HIV-1 replication in vitro by vaccine-induced human CD8+ T cells through conserved subdominant Pol epitopes. <i>Vaccine</i> , 2016, 34, 1215-1224.	3.8	35
44	Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques. <i>Immunity, Inflammation and Disease</i> , 2015, 3, 82-93.	2.7	8
45	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. <i>Journal of Translational Medicine</i> , 2015, 13, 60.	4.4	84
46	Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses. <i>PLoS Pathogens</i> , 2015, 11, e1004658.	4.7	42
47	Transient IL-10 receptor blockade can enhance CD8+T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1030-1035.	3.3	7
48	Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells. <i>Journal of Virology</i> , 2015, 89, 5760-5771.	3.4	32
49	Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial. <i>PLoS ONE</i> , 2014, 9, e101591.	2.5	72
50	Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14017.	4.1	18
51	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475.	8.2	188
52	Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 601-616.	3.1	57
53	Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice. <i>Vaccine Journal</i> , 2014, 21, 1565-1572.	3.1	22
54	PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi. <i>Vaccine</i> , 2014, 32, 5801-5808.	3.8	13

#	ARTICLE	IF	CITATIONS
55	A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A76-A76.	1.1	0
56	Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines. <i>Aids</i> , 2014, 28, 2495-2504.	2.2	10
57	Infant Neutropenia Associated with Breastfeeding During Maternal Antiretroviral Treatment for Prevention of Mother-to-Child Transmission of HIV. <i>Retrovirology: Research and Treatment</i> , 2014, 6, 1.	1.0	1
58	Critical Role of Endoplasmic Reticulum Aminopeptidase 1 in Determining the Length and Sequence of Peptides Bound and Presented by HLA-B*27. <i>Arthritis and Rheumatology</i> , 2014, 66, 284-294.	5.6	71
59	Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsv, in HAART-treated Subjects. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A190-A190.	1.1	1
60	Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A187-A187.	1.1	1
61	Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. <i>Journal of Immunological Methods</i> , 2014, 409, 161-173.	1.4	28
62	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. <i>PLoS ONE</i> , 2014, 9, e114709.	2.5	11
63	Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. <i>Vaccine</i> , 2013, 31, 5594-5601.	3.8	12
64	DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. <i>Aids</i> , 2013, 27, 2841-2851.	2.2	21
65	A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants. <i>PLoS ONE</i> , 2013, 8, e78289.	2.5	17
66	Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine. <i>Journal of Virology</i> , 2012, 86, 4082-4090.	3.4	50
67	Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. <i>Aids</i> , 2012, 26, 275-284.	2.2	35
68	T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric E-co-HIV/NDK challenge virus load. <i>European Journal of Immunology</i> , 2012, 42, 3243-3255.	2.9	18
69	Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vected by Lysine Auxotroph of BCG. <i>PLoS ONE</i> , 2012, 7, e42559.	2.5	15
70	Mice Chronically Infected with Chimeric HIV Resist Peripheral and Brain Superinfection: A Model of Protective Immunity to HIV. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 380-387.	4.1	33
71	Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis. <i>PLoS ONE</i> , 2011, 6, e20067.	2.5	27
72	Optimizing HIV-specific CD8 <sup>+</sup> T cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. <i>European Journal of Immunology</i> , 2011, 41, 3542-3552.	2.9	27

#	ARTICLE	IF	CITATIONS
73	HIV-1: From escapism to conservatism. <i>European Journal of Immunology</i> , 2011, 41, 3390-3393.	2.9	14
74	Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges. <i>PLoS Pathogens</i> , 2011, 7, e1002041.	4.7	62
75	Newborn Mice Vaccination with BCG.HIV-1 + MVA.HIV-1 Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-11.	3.3	19
76	Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. <i>European Journal of Immunology</i> , 2010, 40, 1973-1984.	2.9	71
77	Novel Recombinant <i>Mycobacterium bovis</i> BCG, Ovine Adenovirus, and Modified Vaccinia Virus Ankara Vaccines Combine To Induce Robust Human Immunodeficiency Virus-Specific CD4 and CD8 T-Cell Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2010, 84, 5898-5908.	3.4	22
78	Safety and Immunogenicity of Novel Recombinant BCG and Modified Vaccinia Virus Ankara Vaccines in Neonate Rhesus Macaques. <i>Journal of Virology</i> , 2010, 84, 7815-7821.	3.4	25
79	Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. <i>Vaccine</i> , 2010, 28, 7306-7312.	3.8	17
80	Blocking Development of a CD8+ T Cell Response by Targeting Lymphatic Recruitment of APC. <i>Journal of Immunology</i> , 2009, 182, 2425-2431.	0.8	35
81	Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN- $\gamma$ ELISPOT assay. <i>European Journal of Immunology</i> , 2009, 39, 975-985.	2.9	23
82	Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101+ patients protected mice against chimaeric ecotropic HIV-1 challenge. <i>European Journal of Immunology</i> , 2009, 39, 1831-1840.	2.9	22
83	Ovine adenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. <i>Vaccine</i> , 2009, 28, 474-483.	3.8	25
84	Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pThr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. <i>Vaccine</i> , 2008, 26, 2788-2795.	3.8	83
85	STEP trial and HIV-1 vaccines inducing T-cell responses. <i>Expert Review of Vaccines</i> , 2008, 7, 303-309.	4.4	28
86	Developing HIV-1 vaccines with a positive attitude. <i>Future HIV Therapy</i> , 2008, 2, 213-216.	0.4	0
87	Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. <i>Journal of General Virology</i> , 2007, 88, 1-12.	2.9	118
88	Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 through Breastfeeding. <i>Journal of Virology</i> , 2007, 81, 9408-9418.	3.4	47
89	Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy. <i>Journal of Immunology</i> , 2007, 179, 597-606.	0.8	24
90	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. <i>Vaccine</i> , 2007, 25, 2120-2127.	3.8	96

#	ARTICLE	IF	CITATIONS
91	Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. <i>Vaccine</i> , 2007, 25, 3277-3283.	3.8	50
92	Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. <i>PLoS ONE</i> , 2007, 2, e984.	2.5	247
93	Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. <i>European Journal of Immunology</i> , 2007, 37, 566-577.	2.9	35
94	Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. <i>Vaccine</i> , 2006, 24, 417-425.	3.8	117
95	On DNA vaccines and prolonged expression of immunogens. <i>European Journal of Immunology</i> , 2006, 36, 806-809.	2.9	8
96	Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. <i>European Journal of Immunology</i> , 2006, 36, 2585-2594.	2.9	30
97	Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine. <i>Journal of Virology</i> , 2006, 80, 4705-4716.	3.4	80
98	Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes. <i>Journal of Virology</i> , 2006, 80, 4717-4728.	3.4	220
99	Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. <i>Journal of General Virology</i> , 2006, 87, 399-410.	2.9	49
100	Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. <i>Aids</i> , 2005, 19, 1321-1323.	2.2	31
101	Altered primary CD8+ T <sub>H</sub> 1 cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T <sub>H</sub> 1 cell help. <i>European Journal of Immunology</i> , 2005, 35, 3460-3467.	2.9	8
102	Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T <sub>H</sub> 1 cell responses. <i>European Journal of Immunology</i> , 2005, 35, 2532-2540.	2.9	54
103	Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. <i>Journal of General Virology</i> , 2005, 86, 349-354.	2.9	40
104	Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen. <i>Journal of Virology</i> , 2005, 79, 14822-14833.	3.4	22
105	Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. <i>Vaccine</i> , 2005, 23, 1507-1514.	3.8	38
106	MVA as a vector for vaccines against HIV-1. <i>Expert Review of Vaccines</i> , 2004, 3, S89-S97.	4.4	37
107	A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. <i>Journal of General Virology</i> , 2004, 85, 911-919.	2.9	206
108	DNA vaccines against human immunodeficiency virus type 1. <i>Immunological Reviews</i> , 2004, 199, 144-155.	6.0	39

#	ARTICLE	IF	CITATIONS
109	Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. <i>Journal of General Virology</i> , 2003, 84, 361-368.	2.9	49
110	A Pilot Study of the Safety and Immunogenicity of An HIV-1 Clade A Gag/Multi-epitope DNA Vaccine, pTHr.HIVA, in HIV-1 Seropositive Subjects Receiving Highly Active Antiretroviral Therapy. <i>Clinical Science</i> , 2003, 104, 54P-54P.	0.0	0
111	Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. <i>Journal of General Virology</i> , 2003, 84, 203-213.	2.9	27
112	Development of prophylactic AIDS vaccines: the current state of affairs. <i>Current Opinion in Molecular Therapeutics</i> , 2003, 5, 25-32.	2.8	8
113	Development of a DNA-MVA/HIVA vaccine for Kenya. <i>Vaccine</i> , 2002, 20, 1995-1998.	3.8	62
114	A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. <i>Journal of General Virology</i> , 2002, 83, 75-80.	2.9	72
115	Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.. <i>Nature Medicine</i> , 2000, 6, 951-955.	30.7	190
116	Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. <i>Journal of General Virology</i> , 1999, 80, 2621-2628.	2.9	25
117	Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multi-epitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen. <i>Journal of Virology</i> , 1999, 73, 7524-7532.	3.4	288
118	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. <i>Nature Medicine</i> , 1998, 4, 397-402.	30.7	640
119	DNA multi-CTL epitope vaccines for HIV and <i>Plasmodium falciparum</i> : immunogenicity in mice. <i>Vaccine</i> , 1998, 16, 426-435.	3.8	125